Antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis Report Keywords – Antibody Drug, Conjugates, Roots Analysis, Biotech, Analysis Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community Roots Analysis is pleased to announce the publication of its recent study, titled, “ Antibody Drug Conjugates Market (5th Edition), 2019-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of ADCs.  Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis